NIDC News

Join Our 2021 Isotope User Group Meetings
The DOE IP will host four virtual isotope user meetings focused on the following emerging alpha-emitters: actinium-225, astatine-211, lead-212, and new this year, copper-67.
Graduate student Paige Abel performing research on isotope harvesting techniques to be used at the FRIB Isotope Harvesting Facility. Photo by: Facility for Rare Isotope Beams, Michigan State University
The FRIB program was recently awarded a grant worth $13 million over the next four years from the Office of Science and supported by the DOE Isotope Program to increase isotope harvesting capabilities.
Isotope Availability July 2021
 The DOE Isotope Program is pleased to announce the availability of some of our most requested isotopes for purchase.

DOE Isotope Program Highlights

Image courtesy of Donald Montoya, Los Alamos National Laboratory Cerium-134 can be targeted to provide an imaging analogue for two different therapy isotopes, actinium-225 and thorium-227. This helps scientists understand these therapy isotopes and develop new treatments. These novel isotopes are being developed and produced by the DOE Isotope Program.

New Imaging Isotope Meets Promising Therapy Isotopes

New production methods for Ce-134 advance technologies for imaging human disease and guiding treatment.
Image courtesy of Jon Burns, Texas A&M University At-211 – ketone interaction within the chromatography column.

New Elegant Method for Rapid Recovery of Anti-Cancer Agent At-211

A high-speed, high-yield recovery approach for At-211 means improved availability of this cancer-treating isotope.
Julie Ezold has been elected to a three-year term on the American Nuclear Society’s Board of Directors.

Ezold elected to the ANS Board of Directors

Julie Ezold, section head at ORNL, has been elected to a three-year term on the American Nuclear Society’s Board of Directors.
Increasing the Arsenal of Radioisotopes in the Fight Against Cancer

Increasing the Arsenal of Radioisotopes in the Fight Against Cancer

A new supply of a critical radioisotope advances personalized medicine.